PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 30912151-0 2019 A large deletion in RYR2 exon 3 is associated with nadolol and flecainide refractory catecholaminergic polymorphic ventricular tachycardia. Nadolol 51-58 ryanodine receptor 2 Homo sapiens 20-24 30912151-1 2019 We report a 17-year-old boy with a large RYR2 exon 3 deletion who has a severe catecholaminergic polymorphic ventricular tachycardia (CPVT) phenotype characterized by refractoriness to both nadolol and flecainide which has previously not been reported in this subgroup of CPVT patients. Nadolol 190-197 ryanodine receptor 2 Homo sapiens 41-45 27491078-4 2016 An individual with CPVT harboring a novel mutation in the type 2 cardiac ryanodine receptor (RyR2) was identified whose persistent ventricular arrhythmias during beta-blockade with nadolol were abolished during flecainide treatment. Nadolol 181-188 ryanodine receptor 2 Homo sapiens 93-97